-

$undefined

N/A

(N/A)

Phathom Pharmaceuticals NASDAQ:PHAT Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders.

Location: | Website: www.phathompharma.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

538.3M

Cash

297.3M

Avg Qtr Burn

-66.69M

Short % of Float

22.80%

Insider Ownership

3.83%

Institutional Own.

97.00%

Qtr Updated

12/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
VOQUEZNA® (vonoprazan)(potassium competitive acid blocker) Details Gastroesophageal reflux disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VOQUEZNA (Vonoprazan)(Potassium competitive acid blocker) Details Intestinal infection, Gastroesophageal reflux disease, Esophagitis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VOQUEZNA (Vonoprazan) (Potassium competitive acid blocker) Details Bacterial infection	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VOQUEZNA® (vonoprazan)(potassium competitive acid blocker) Details Gastroesophageal reflux disease	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VOQUEZNA® (Vonoprazan)(potassium competitive acid blocker) Details Eosinophilic Esophagitis	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.